Trial Profile
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Methotrexate (Primary) ; Regorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jul 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2022 Planned End Date changed from 1 Mar 2022 to 1 Apr 2023.